InvestorsHub Logo
Followers 20
Posts 1528
Boards Moderated 0
Alias Born 05/27/2015

Re: None

Tuesday, 01/24/2017 5:12:56 PM

Tuesday, January 24, 2017 5:12:56 PM

Post# of 731418
How can anybody say that the current PH3 is in trouble when the brand new trial with Opdivo (NCT03014804) is comparing the following?

GROUP I: Patients receive DCVax-L intradermally (ID) on days 0, 7, 14, and weeks 4, 6, 8, 11, 14, 17 and 20.

GROUP II: Patients receive DCVax-L as in Group I, and Opdivo intravenously (IV) over 30 minutes on days 0, 14, and weeks 4, 6, 8, 11, 14, 17, and 20.

Why can this not be comprehended by so many?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News